CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
3.090
-0.050 (-1.59%)
May 29, 2026, 1:26 PM EDT - Market open
CervoMed Revenue
CervoMed had revenue of $2.09M in the twelve months ending March 31, 2026, down -77.56% year-over-year. In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%.
Revenue (ttm)
$2.09M
Revenue Growth
-77.56%
P/S Ratio
13.92
Revenue / Employee
$139,268
Employees
15
Market Cap
28.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Barinthus Biotherapeutics | 14.97M |
| Apollomics | 8.84M |
| Kyntra Bio | 7.44M |
| IGC Pharma | 1.11M |
| Lisata Therapeutics | 170.00K |
| Serina Therapeutics | 130.00K |
| Neuphoria Therapeutics | -13.27K |
CRVO News
- 10 days ago - CervoMed price target lowered to $9 from $11 at Roth Capital - TheFly
- 11 days ago - CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 14 days ago - CervoMed Quarterly report: Q1 2026 - Filings
- 14 days ago - CervoMed Earnings release: Q1 2026 - Filings
- 4 weeks ago - CervoMed Proxy statement: Proxy filing - Filings
- 5 weeks ago - CervoMed presents neflamapimod MRI data - TheFly
- 5 weeks ago - CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - GlobeNewsWire
- 7 weeks ago - CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - GlobeNewsWire